Breaking News —

Whether administered alone or with an antibiotic from the macrolide group, these drugs increase the lethal risk for patients from 1.27 to 1.53 times.

Hydroxychloroquine and chloroquine do not increase but markedly reduce the chances of survival in patients with the coronavirus, say the authors of an article published this Friday in The Lancet.

To test the efficiency of these drugs – originally developed for the treatment of malaria – specialist doctors analyzed the medical records of more than 96,000 patients from 671 hospitals on six continents of the world. They divided the total of the cases into four groups: those receiving the chloroquine treatment; chloroquine and a macrolide (group of antibiotics to which azithromycin belongs, among others); hydroxychloroquine; and hydroxychloroquine with a macrolide. All the others (except those taking remdesevir or starting treatment two days after diagnosis or requiring ventilators) were included in a control group.

After determining the mortality rate for each set separately, the scientists found that they differed considerably. At control group, they died a 9.3% of the patients, which was less than the average (11.1%). However, among those who took chloroquine the mortality was 16.4%; with chloroquine plus a macrolide, 22.2%; hydroxychloroquine, 18%; and hydroxychloroquine with a macrolide, 23.8%.

Thus, treatment with such drugs increased the risk of death. 1.27 to 1.53 times, depending on the specific plan.

We were unable to confirm a benefit provided by hydroxychloroquine or chloroquine, when used alone or with a macrolide. […] Each of these drug regimens was associated with a decreased survival in hospital and increased frequency of ventricular arrhythmias when used to treat covid-19 “, doctors warn.